ArticlePediatric endocrinology, diabetes, and metabolism2024
Assessment of the concentration of osteoprotegerin and receptor activator of nuclear factor kB ligand in healthy children.
Article in Pediatric endocrinology, diabetes, and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe OPG/RANKL ratio is an important determinant of bone mass and skeletal integrity, and it is also crucial in the pathogenesis of bone diseases. So far, few studies have been conducted to determine the reference values of OPG and RANKL in developmental age. AIM OF THE STUDY: The aim of the study was to determine the reference values of OPG, sRANKL concentrations and the OPG/RANKL ratio in healthy children, as well as to assess the impact of selected demographic factors and biological development on their concentrations. MATERIAL AND
methodsData obtained from medical records of 56 healthy patients aged 1-18 years were analyzed. Anthropometric measurements were analyzed for each child and the stage of puberty was assessed using the standard Tanner scale criteria. OPG and sRANKL levels were determined by ELISA with kits from Biomedica. The osteoprotegerin bioactivity index (OPG/RANKL ratio) was calculated for each patient by dividing OPG values by sRANKL (OPG/RANKL ratio).
resultsIn the studied population of healthy children and adolescents, the OPG serum concentration reference value was established at 3.15-4.90 pmol/l, sRANKL at 0.20-0.60 pmol/l, and the OPG/RANKL ratio at 7.40-20.00. Serum OPG, sRANKL and OPG/RANKL levels did not change significantly with gender, BMI and Tanner stage of puberty. A statistically significant negative correlation was found between age and OPG levels (r = -0.32, p = 0.0168) and OPG/RANKL ratio (r = -0.34, p = 0.0228).
conclusionsIn healthy children and adolescents, OPG levels decrease with age, but the influence of puberty and body weight on OPG and sRANKL levels requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.